BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22663138)

  • 1. Nalfurafine hydrochloride for the treatment of pruritus.
    Inui S
    Expert Opin Pharmacother; 2012 Jul; 13(10):1507-13. PubMed ID: 22663138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
    Nakao K; Mochizuki H
    Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
    Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
    Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
    Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
    Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
    Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
    Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
    Miyamoto Y; Oh T; Aihara E; Ando A
    Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
    Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients.
    Inui S; Shirakawa Y; Itami S
    J Dermatol; 2012 Oct; 39(10):886-7. PubMed ID: 22142516
    [No Abstract]   [Full Text] [Related]  

  • 9. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
    J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
    Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
    Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
    Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
    Nakao K; Ando A; Hirakata M; Ando N; Takeshita K; Miyamoto Y; Mochizuki H
    Nihon Yakurigaku Zasshi; 2010 May; 135(5):205-14. PubMed ID: 20467170
    [No Abstract]   [Full Text] [Related]  

  • 13. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
    Inan S; Cowan A
    Pharmacol Biochem Behav; 2006 Sep; 85(1):39-43. PubMed ID: 16919318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
    Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
    Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
    Inan S; Dun NJ; Cowan A
    Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.
    Kawano T; Atsukawa M; Tsubota A; Shimada N; Toyoda H; Takaguchi K; Tani J; Morishita A; Hiraoka A; Mikami S; Ishikawa T; Okubo H; Watanabe T; Okubo T; Arai T; Hayama K; Itokawa N; Kondo C; Iwakiri K
    Sci Rep; 2022 May; 12(1):7311. PubMed ID: 35508514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
    Schattauer SS; Kuhar JR; Song A; Chavkin C
    Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
    Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
    J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride.
    Nakamoto H; Kobayashi T; Noguchi T; Kusano T; Ashitani K; Imaeda H; Maezono M
    Blood Purif; 2019; 47 Suppl 2():45-49. PubMed ID: 30943482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
    Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
    Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.